Arax Advisory Partners’s ADMA Biologics ADMA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$70.1K Buy
8,377
+7,408
+764% +$67.5K ﹤0.01% 2998
2026
Q1
$8.73K Buy
969
+603
+165% +$9.52K ﹤0.01% 2518
2025
Q4
$6.68K Sell
366
-1,033
-74% -$17.4K ﹤0.01% 2696
2025
Q3
$20.5K Buy
+1,399
New +$24K ﹤0.01% 2255
2025
Q1
Sell
-782
Closed -$13.4K 2665
2024
Q4
$13.4K Hold
782
﹤0.01% 1374
2024
Q3
$15.6K Hold
782
﹤0.01% 1189
2024
Q2
$8.74K Buy
+782
New +$6.56K ﹤0.01% 1335

Other funds holding ADMA

Arax Advisory Partners's ADMA Position: Q2 2026 in Review

Arax Advisory Partners increased its ADMA Biologics (ADMA) stake by 764% in Q2 2026, buying an estimated $67.5K and bringing the position to 8,377 shares worth $70.1K. The position accounts for ﹤0.01% of the portfolio, ranked #2998.

Arax Advisory Partners first reported a position in ADMA in Q2 2024 and has held it in 7 quarters since. 323 funds tracked by Wall St. Rank hold ADMA as of Q2 2026.

  • Arax Advisory Partners held 8,377 shares of ADMA Biologics worth $70.1K as of Q2 2026.
  • Arax Advisory Partners bought 7,408 ADMA Biologics shares in Q2 2026, an estimated $67.5K.
  • ADMA Biologics made up ﹤0.01% of Arax Advisory Partners's portfolio in Q2 2026, its #2998 holding.
  • Arax Advisory Partners first reported a position in ADMA Biologics in Q2 2024 and has held it in 7 quarters since.
  • 323 funds tracked by Wall St. Rank held ADMA Biologics as of Q2 2026.

Based on Arax Advisory Partners's 13F filing for Q2 2026, filed 10 Aug 2026.